DTaP5-IPV-Hib Vaccine (Pediacel®)

Esposito S, Principi N. Differences in vaccinations in European Union. Hum Vaccin 2008; 4 (4): 313–5 United Nations Children’s Fund. Immunization summary: the 2007 edition [online]. Available from URL: http://www.unicef.org/publications/files/Immunization_Summary_2007.pdf [Accessed 2011 May 25] Dhillon S, Keam SJ. DTaP-IPV/Hib vaccine (Pentacel®). Pediatr Drugs 2008; 10 (6): 405–16 Dhillon S. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™): a review of its use as primary and booster vaccination. Drugs 2010 May 28; 70 (8): 1021–58 Sanofi Pasteur Limited. Quadracel® (diphtheria and tetanus toxoids, acellular pertussis adsorbed combined with inactivated poliomyelitis vaccine): suspension for injection. Product monograph [online]. Available from URL: https://www.vaccineshoppecanada.com/secure/pdfs/ca/quadrACEL_E.pdf [Accessed 2011 May 25] Infanrix-IPV (diphtheria, tetanus, pertussis [acellular component] and poliomyelitis [inactivated] vaccine [adsorbed]): summary of product characteristics. Uxbridge: GlaxoSmithKline, 2010 Actacel™: concise prescribing information. Singapore: Zuellig Pharma, 2011 Pediacel (diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine [adsorbed]): summary of product characteristics. Maidenhead: Sanofi Pasteur MSD Ltd, 2010 Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate [tetanus toxoid conjugate]) vaccine: suspension for intramuscular injection (US prescribing information). Swiftwater (PA): Sanofi Pasteur Inc., 2009 Pediarix (diphtheria and tetanus toxoids and acellular pertussis adsorbed, Hepatitis B [recombinant] and inactivated poliovirus vaccine): suspension for intramuscular injection (US prescribing information). Research Triangle Park (NC): GlaxoSmithKline Inc., 2010 Infanrix-IPV+Hib (diphtheria, tetanus, pertussis [acellular component], poliomyelitis [inactivated] and Haemophilus type b conjugate vaccine [adsorbed]): summary of product characteristics. Uxbridge: GlaxoSmithKline, 2009 Capeding MR, Cadorna-Carlos J, Book-Montellano M, et al. Immunogenicity and safety of a DTaP-IPV//PRP∼T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bull WHO 2008; 86 (6): 443–51 Pentavac® (diphtheria, tetanus, pertussis [acellular, component], poliomyelitis [inactivated] and Haemophilus influenzae type b conjugate vaccine [adsorbed]): summary of product characteristics. Brussels: Sanofi Pasteur MSD, 2010 European Medicines Agency. Infanrix hexa™. Annex I: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000296/WC500032505.pdf [Accessed 2011 May 25] Grimprel E, Wysocki J, Boisnard F, et al. Immunogenicity and safety of fully liquid DTaP5-IPV-Hib compared with DTaP3-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, and 4, and 12 to 18 months of age: a phase III, single-blind, randomized, controlled, multicentre study. Vaccine 2011; 29 (43): 7370–8 Lin TY, Wang YH, Chang LY, et al. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. Int J Infect Dis 2007 Mar; 11 (2): 129–36 Wiedenmayer KA, Weiss S, Chattopadhyay C, et al. Simplifying paediatric immunization with a fully liquid DTP-HepB-Hib combination vaccine: evidence from a comparative time-motion study in India. Vaccine 2009; 27: 655–9 Andrews N, Stowe J, Wise L, et al. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine 2010 Oct 18; 28 (44): 7215–20 Southern J, Borrow R, Andrews N, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009 Feb; 16 (2): 194–9 Moss SJ, Fenton AC, Toomey J, et al. Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type B vaccine and a meningococcal group C conjugate vaccine at 2, 3, and 4 months of age. Clin Vaccine Immunol 2010 Mar; 17 (3): 311–6 Medicines and Healthcare products Regulation Agency. Public assessment report decentralized procedure: Pediacel suspension for injection in pre-filled syringe [procedure no.: UK/H/2388/01/DC; UK licence no.: PL 06745/0128; online]. Available from URL: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con108611.pdf [Accessed 2011 May 22] Vesikari T, Silfverdal SA, Boisnard F, et al. Immunogenicity and safety of a fully liquid DTaP5-IPV-Hib versus DTaP3-IPV/Hib at 3, 5, and 12 months of age [abstract plus poster]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4–8; Nice Kitchin NR, Southern J, Morris R, et al. Evaluation of a diphtheria-tetanusacellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 2007 Jan; 92 (1): 11–6 Kitchin N, Southern J, Morris R, et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine 2009 Aug 13; 27 (37): 5096–102 Gold R, Barreto L, Ferro S, et al. Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age. Can J Infect Dis Med Microbiol 2007 Jul; 18 (4): 241–8 Berner R, Boisnard F, Thomas S, et al. Safety and immunogenicity of fully liquid DTaP5-IPV-Hib versus DTaP3-HBV-IPV/Hib as a booster at 11–18 months of age coadministered with PCV7 [abstract plus poster]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4–8; Nice Sanofi Pasteur Limited. Pediacel® (diphtheria and tetanus toxoids, acellular pertussis adsorbed combined with inactivated poliomyelitis vaccine and Haemophilus b conjugate vaccine [tetanus protein - conjugate]) — suspension for injection: product monograph [online]. Available from URL: https://www.vaccineshoppecanada.com/secure/pdfs/ca/Pediacel_E.pdf [Accessed 2011 Jun 13] Lin TY, Wang YH, Huang YC, et al. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Int J Infect Dis 2007 Nov; 11 (6): 488–95 Capeding MR, Unalivia L, Victorio MV, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-Hib vaccine in infants at 6, 10, 14 weeks of age (EPI schedule) [poster]. 3rd World Congress of Pediatric Infectious Diseases (WSPID); 2002 Nov 19–23; Santiago Castaneda JL, Gonzalez N, Chavez R, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-Hib vaccine with full primary IPV or sequential IPV-OPV in Mexican infants [poster]. 11th International Congress on Infectious Diseases (ICID); 2004 Mar 4–7; Cancun Klinger CL, Snape MD, John T, et al. Immunogenicity of DTaP-IPV-Hib and MenC vaccines in the UK when administered with a 13-valent pneumococcal conjugate vaccine [abstract no. GI-2118]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, and 46th Annual Meeting of the Infectious Diseases Society of America — a joint meeting; 2008 Oct 25–28; Washington, DC Frampton JE. DTaP5-IPV-Hib Vaccine (Pediacel®). Pediatr Drugs 2011; 13 (6): 401–15